Dr Richard Hoglund
Head of Pharmacometrics
Richard Hoglund heads the pharmacometrics group at the department of Clinical Pharmacology, MORU. He has a background in chemical engineering and pharmacology and his research is mainly focused on pharmacometrics, pharmacokinetics, pharmacodynamics and mathematical modelling in tropical medicine research, with a particular focus on antimalarial therapy.
More specific, his main research aims to optimise current and future antimalarial therapies by utilizing pharmacometric methodologies. A pharmacometric modelling approach can identify specific groups at risk of treatment failure and the derived pharmacometric models can help to evaluate and suggest new dose regimens to improve the treatment of malaria.
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics.
Wattanakul T. et al, (2022), Expert Rev Clin Pharmacol
Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
Assmus F. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010219 - e0010219
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M. et al, (2021), The Lancet. Infectious diseases, 21, 1395 - 1406
Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence".
Ding J. et al, (2021), Clinical pharmacology and therapeutics, 110, 24 - 25
Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa
Fanello C. et al, (2021), Antimicrobial Agents and Chemotherapy, 65